Skip to main content

Table 1 Association between JAK1 expression and prognosis with different clinicopathological features of NSCLC by Kaplan–Meier plotter

From: The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC

Clinicopathological characteristics

Overall survival (n = 1144)

Progression-free survival (n = 596)

N

HR

P value

N

HR

P value

Gender

 Male

659

0.64 (0.52–0.79)

2.20E−05

343

0.61 (0.43–0.86)

0.0043

 Female

374

0.86 (0.61–1.21)

0.38

253

0.77 (0.49–1.20)

0.25

Stage

 1

449

1.46 (1.06–2.00)

0.02

596

1.26 (0.81–1.95)

0.31

 2

161

0.99 (0.63–1.55)

0.95

125

0.64 (0.38–1.11)

0.108

 3

44

1.11 (0.55–2.25)

0.77

17

–

–

AJCC stage T

 1

224

0.86 (0.57–1.28)

0.44

54

0.95 (0.23–3.53)

0.94

 2

190

0.86 (0.58–1.27)

0.44

121

1.75 (0.94–3.27)

0.073

 3

29

0.83 (0.38–1.85)

0.65

2

–

–

 4

23

0.74 (0.30–1.84)

0.52

0

–

–

AJCC stage N

 0

324

0.87 (0.63–1.19)

0.38

126

2.18 (1.06–4.46)

0.029

 1

102

0.64 (0.38–1.08)

0.09

51

0.98 (0.40–2.41)

0.96

 2

32

0.39 (0.17–0.86)

0.016

0

–

–

AJCC stage M

 0

462

0.73 (0.56–0.93)

0.013

177

1.66 (0.95–2.9)

0.07

Smoking history

 Yes

300

1.59 (1.04–2.24)

0.029

297

0.73 (0.48–1.08)

0.11

 No

141

2.24 (0.96–5.25)

0.056

141

1.39 (0.75–2.58)

0.29

Chemotherapy

 Yes

34

0.82 (0.26–2.64)

0.74

34

1.18 (0.45–3.11)

0.74

 No

21

0.18 (0.02–1.52)

0.075

21

0.63 (0.19–2.07)

0.44

  1. N Number, HR Hazard Ratio